Ftse Mib
34.492,41
0,13%
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
NASDAQ
16.735,02
-0,01%
Bitcoin
68.152,14
0,63%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Cognition Therapeutics Inc (CGTX) Cognition Therapeutics Inc (CGTX) Notizie

CGTX

Cognition Therapeutics (CGTX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CGTX
DataOraFonteTitoloSimboloCompagnia
07/05/202413:45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CGTXCognition Therapeutics Inc
07/05/202413:39Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGTXCognition Therapeutics Inc
11/03/202421:06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CGTXCognition Therapeutics Inc
20/02/202422:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGTXCognition Therapeutics Inc
19/01/202421:07Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CGTXCognition Therapeutics Inc
09/01/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CGTXCognition Therapeutics Inc
08/01/202422:11Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:CGTXCognition Therapeutics Inc
04/01/202413:30GlobeNewswire Inc.Cognition Therapeutics CEO Issues Letter to ShareholdersNASDAQ:CGTXCognition Therapeutics Inc
29/12/202322:02Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CGTXCognition Therapeutics Inc
16/11/202313:30GlobeNewswire Inc.Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip ScheltensNASDAQ:CGTXCognition Therapeutics Inc
15/11/202313:30GlobeNewswire Inc.Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s DiseasesNASDAQ:CGTXCognition Therapeutics Inc
13/11/202323:25Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:CGTXCognition Therapeutics Inc
13/11/202323:17Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CGTXCognition Therapeutics Inc
07/11/202313:30GlobeNewswire Inc.Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s DiseaseNASDAQ:CGTXCognition Therapeutics Inc
02/11/202312:30GlobeNewswire Inc.Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:CGTXCognition Therapeutics Inc
27/10/202313:30GlobeNewswire Inc.Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTADNASDAQ:CGTXCognition Therapeutics Inc
24/10/202322:30GlobeNewswire Inc.Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTADNASDAQ:CGTXCognition Therapeutics Inc
16/10/202313:30GlobeNewswire Inc.Cognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS IndicationsNASDAQ:CGTXCognition Therapeutics Inc
07/09/202313:45GlobeNewswire Inc.Cognition Therapeutics Announces New Conversations Episode on Therapeutic Strategies to Protect the Retina in Dry AMDNASDAQ:CGTXCognition Therapeutics Inc
30/08/202314:00GlobeNewswire Inc.Cognition Therapeutics Announces Participation in Upcoming September ConferencesNASDAQ:CGTXCognition Therapeutics Inc
08/08/202313:00GlobeNewswire Inc.Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business UpdateNASDAQ:CGTXCognition Therapeutics Inc
02/08/202313:30GlobeNewswire Inc.Cognition Therapeutics to Report Second Quarter 2023 Results in Conference Call on Tuesday, August 8, 2023NASDAQ:CGTXCognition Therapeutics Inc
11/07/202313:30GlobeNewswire Inc.Cognition Therapeutics Announces Dosing of First Patient in MAGNIFY Study of Oral CT1812 for Geographic Atrophy Secondary to Dry AMDNASDAQ:CGTXCognition Therapeutics Inc
05/07/202313:30GlobeNewswire Inc.Cognition Therapeutics and the Alzheimer's Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 START Study in Early Alzheimer’s DiseaseNASDAQ:CGTXCognition Therapeutics Inc
28/06/202313:33Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:CGTXCognition Therapeutics Inc
28/06/202313:28Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CGTXCognition Therapeutics Inc
28/06/202313:00GlobeNewswire Inc.Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s DiseaseNASDAQ:CGTXCognition Therapeutics Inc
28/06/202301:17GlobeNewswire Inc.Cognition Therapeutics to Host Call and Webcast to Discuss Topline Results from CT1812 Phase 2 SEQUEL Study on June 28, 2023NASDAQ:CGTXCognition Therapeutics Inc
20/06/202313:30GlobeNewswire Inc.Cognition Therapeutics Invited to Participate on Panel During Cantor Fitzgerald Brain Week 2023 on Novel Alzheimer’s Disease ApproachesNASDAQ:CGTXCognition Therapeutics Inc
13/06/202323:38Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CGTXCognition Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CGTX

La tua Cronologia

NYSE
IHS
IHS
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network